EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Atogepant: Mechanism of action, clinical and translational science

Ramesh Boinpally iD, Mohamad Shebley iD, Joel M Trugman iD

Clinical and Translational Science · 2024-01 · 17 (1)

DOI: 10.1111/cts.13707 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 10.01.2024. Verfasst von Ramesh Boinpally und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie, North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Translational Science, Biomedical, Migraine Disorders, Piperidines, Pyridines. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Since the discovery of calcitonin gene‐related peptide (CGRP) in 1982, its integral role in migraine pathophysiology, specifically migraine pain, has been demonstrated through cumulative scientific discoveries that have led to the development and approval of migraine‐specific therapeutics. Today, eight drugs, including monoclonal antibodies and small molecule CGRP receptor antagonists, known as gepants, have received approval for acute or preventive treatment of migraine. The primary mechanism of these drugs is to block CGRP signaling, thus preventing CGRP‐mediated nociception and neurogenic inflammation. Here, we focus on atogepant, a highly potent and selective gepant and the first and only oral medication approved for the preventive treatment of both episodic and chronic migraine in adults. In this article, we summarize the role of CGRP in migraine pathophysiology and the mechanism of action of atogepant. In addition, we provide an overview of atogepant's pharmacology and the key clinical trials and outcomes that have demonstrated the safety and efficacy of atogepant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Translational Science, BiomedicalMigraine DisordersPiperidinesPyridinesPyrrolesSpiro CompoundsAdultHumansCalcitonin Gene-Related PeptideAntibodies, Monoclonal

Substanzen

atogepantCalcitonin Gene-Related PeptideAntibodies, MonoclonalPiperidinesPyridinesPyrrolesSpiro Compounds

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie, North Chicago, Illinois, USA.
  • Clinical Development, AbbVie, North Chicago, Illinois, USA.

ORCID-Profile: Ramesh Boinpally, Mohamad Shebley, Joel M Trugman

Zitieren

APA

Boinpally, R., Shebley, M., & Trugman, J. M. (2024). Atogepant: Mechanism of action, clinical and translational science. Clinical and Translational Science, 17(1). https://doi.org/10.1111/cts.13707

Vancouver

Boinpally R, Shebley M, Trugman JM. Atogepant: Mechanism of action, clinical and translational science. Clinical and Translational Science. 2024;17(1). doi:10.1111/cts.13707

BibTeX
@article{Boinpally2024,
  author = {Boinpally, Ramesh and Shebley, Mohamad and Trugman, Joel M},
  title = {Atogepant: Mechanism of action, clinical and translational science},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {1},
  doi = {10.1111/cts.13707}
}
Kostenlos starten →